Innoviva, Inc. (NASDAQ:INVA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Innoviva, Inc. (NASDAQ:INVA) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $38.1667.

INVA has been the subject of a number of research reports. HC Wainwright lifted their target price on shares of Innoviva from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “buy (b)” rating on shares of Innoviva in a research report on Monday, December 29th. Zacks Research downgraded Innoviva from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Cantor Fitzgerald raised their price target on Innoviva from $29.00 to $31.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, BTIG Research reiterated a “buy” rating and set a $35.00 price target on shares of Innoviva in a report on Thursday, February 26th.

Innoviva News Roundup

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and set a $46.00 price target, providing fundamental support for a higher valuation if the firm’s longer‑term forecasts materialize. Article Title
• Positive Sentiment: The analyst now projects much stronger FY2027 earnings of $2.50 per share, signaling expected improvement in cash flow or royalty income beyond 2026 that could drive upside over the next 12–24 months. Article Title
• Neutral Sentiment: HC Wainwright provided a detailed set of quarterly EPS forecasts for 2027 (Q1: $0.53, Q2: $0.65, Q3: $0.63, Q4: $0.69), which clarifies the firm’s expectations but will matter only if actual results or company guidance track those numbers. Article Title
• Negative Sentiment: HC Wainwright trimmed FY2026 EPS to $1.96 from $2.23, lowering near‑term earnings expectations and creating downward pressure on the stock while investors digest the reduced 2026 outlook. Article Title
• Negative Sentiment: Multiple 2026 quarterly estimates were cut (Q1 2026: $0.42 from $0.45; Q2 2026: $0.51 from $0.56; Q3 2026: $0.48 from $0.57; Q4 2026: $0.55 from $0.66), increasing concern about near‑term earnings momentum and likely contributing to today’s price decline. Article Title

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Elevation Point Wealth Partners LLC bought a new position in shares of Innoviva during the 2nd quarter valued at $43,000. EverSource Wealth Advisors LLC increased its position in Innoviva by 297.7% during the second quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,795 shares during the last quarter. Danske Bank A S bought a new position in Innoviva during the third quarter valued at about $55,000. Asset Management One Co. Ltd. acquired a new stake in shares of Innoviva in the third quarter worth about $60,000. Finally, Toth Financial Advisory Corp acquired a new stake in shares of Innoviva in the third quarter worth about $63,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Price Performance

NASDAQ INVA opened at $22.18 on Friday. The company has a 50 day simple moving average of $21.09 and a 200-day simple moving average of $20.14. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.64 and a quick ratio of 13.85. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of 7.27 and a beta of 0.42. Innoviva has a 52-week low of $16.52 and a 52-week high of $25.15.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $1.60. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. The firm had revenue of $114.61 million for the quarter, compared to the consensus estimate of $102.62 million. Equities research analysts predict that Innoviva will post 0.33 earnings per share for the current fiscal year.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.